Overview
The marketing authorisation for Zurampic has been withdrawn at the request of the marketing-authorisation holder.
Zurampic : EPAR - Summary for the public
English (EN) (670.89 KB - PDF)
български (BG) (766.38 KB - PDF)
español (ES) (667.19 KB - PDF)
čeština (CS) (745.71 KB - PDF)
dansk (DA) (665.65 KB - PDF)
Deutsch (DE) (675 KB - PDF)
eesti keel (ET) (664.65 KB - PDF)
ελληνικά (EL) (797.09 KB - PDF)
français (FR) (669.95 KB - PDF)
hrvatski (HR) (692.16 KB - PDF)
italiano (IT) (665.27 KB - PDF)
latviešu valoda (LV) (745.3 KB - PDF)
lietuvių kalba (LT) (696.61 KB - PDF)
magyar (HU) (740.39 KB - PDF)
Malti (MT) (748.22 KB - PDF)
Nederlands (NL) (666.54 KB - PDF)
polski (PL) (745.3 KB - PDF)
português (PT) (667.58 KB - PDF)
română (RO) (695.55 KB - PDF)
slovenčina (SK) (745.61 KB - PDF)
slovenščina (SL) (736.92 KB - PDF)
Suomi (FI) (665.54 KB - PDF)
svenska (SV) (666.38 KB - PDF)
Zurampic : EPAR - Risk-management-plan summary
English (EN) (646.13 KB - PDF)
Product information
Zurampic : EPAR - Product Information
English (EN) (954.17 KB - PDF)
български (BG) (1.76 MB - PDF)
español (ES) (1.11 MB - PDF)
čeština (CS) (1.44 MB - PDF)
dansk (DA) (1007.97 KB - PDF)
Deutsch (DE) (989.18 KB - PDF)
eesti keel (ET) (952.47 KB - PDF)
ελληνικά (EL) (1.72 MB - PDF)
français (FR) (1019.21 KB - PDF)
hrvatski (HR) (965.33 KB - PDF)
íslenska (IS) (998.87 KB - PDF)
italiano (IT) (998.56 KB - PDF)
latviešu valoda (LV) (1.65 MB - PDF)
lietuvių kalba (LT) (995.1 KB - PDF)
magyar (HU) (1.44 MB - PDF)
Malti (MT) (1.48 MB - PDF)
Nederlands (NL) (969.94 KB - PDF)
norsk (NO) (1.06 MB - PDF)
polski (PL) (1.44 MB - PDF)
português (PT) (994.6 KB - PDF)
română (RO) (1012.13 KB - PDF)
slovenčina (SK) (1.53 MB - PDF)
slovenščina (SL) (1.51 MB - PDF)
Suomi (FI) (973.31 KB - PDF)
svenska (SV) (962.77 KB - PDF)
Latest procedure affecting product information: IA/0008
15/06/2017
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Zurampic : EPAR - All Authorised presentations
English (EN) (602.77 KB - PDF)
български (BG) (625.33 KB - PDF)
español (ES) (600.63 KB - PDF)
čeština (CS) (617.96 KB - PDF)
dansk (DA) (602.13 KB - PDF)
Deutsch (DE) (602.13 KB - PDF)
eesti keel (ET) (594.5 KB - PDF)
ελληνικά (EL) (624.82 KB - PDF)
français (FR) (600.35 KB - PDF)
hrvatski (HR) (601.1 KB - PDF)
íslenska (IS) (601.08 KB - PDF)
italiano (IT) (600.85 KB - PDF)
latviešu valoda (LV) (618.91 KB - PDF)
lietuvių kalba (LT) (601.91 KB - PDF)
magyar (HU) (617.04 KB - PDF)
Malti (MT) (618.15 KB - PDF)
Nederlands (NL) (600.81 KB - PDF)
norsk (NO) (602 KB - PDF)
polski (PL) (617.96 KB - PDF)
português (PT) (601.06 KB - PDF)
română (RO) (600.99 KB - PDF)
slovenčina (SK) (618.33 KB - PDF)
slovenščina (SL) (616.75 KB - PDF)
Suomi (FI) (600.56 KB - PDF)
svenska (SV) (600.56 KB - PDF)
Product details
- Name of medicine
- Zurampic
- Active substance
- lesinurad
- International non-proprietary name (INN) or common name
- lesinurad
- Therapeutic area (MeSH)
- Hyperuricemia
- Anatomical therapeutic chemical (ATC) code
- M04AB05
Pharmacotherapeutic group
Antigout preparationsTherapeutic indication
Zurampic, in combination with a xanthine oxidase inhibitor, is indicated in adults for the adjunctive treatment of hyperuricaemia in gout patients (with or without tophi) who have not achieved target serum uric acid levels with an adequate dose of a xanthine oxidase inhibitor alone.
Authorisation details
- EMA product number
- EMEA/H/C/003932
- Marketing authorisation holder
- Grünenthal GmbH
Zieglerstr. 6
D-52078Aachen
Germany - Marketing authorisation issued
- 18/02/2016
- Revision
- 4
Assessment history
Zurampic : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (765.72 KB - PDF)
News on Zurampic
Public statement on Zurampic: Withdrawal of the marketing authorisation in the European Union
English (EN) (125.47 KB - PDF)
Related information
- Zurampic: Clinical data (initial marketing authorisation)